Structures by: Pop M.
Total: 8
C26H23Cl2N4O4,C7H7NO2
C26H23Cl2N4O4,C7H7NO2
Molecular pharmaceutics (2020)
a=9.7532(4)Å b=13.0997(6)Å c=14.7094(7)Å
α=65.035(5)° β=72.196(4)° γ=84.857(4)°
C26H23Cl2N4O4,C7H7NO2
C26H23Cl2N4O4,C7H7NO2
Molecular pharmaceutics (2020)
a=9.6678(5)Å b=12.9865(6)Å c=14.6942(7)Å
α=64.386(5)° β=71.962(4)° γ=85.754(4)°
(La0.8 Al0.2) (B O3)
Al0.2BLa0.8O3
Modern Physics Letters B (2002) 16, 915-921
a=5.871Å b=5.099Å c=8.239Å
α=90° β=90° γ=90°
Β-2 LaOLa
C45H84O6
Acta Crystallographica Section B (2008) 64, 6 771-779
a=12.0497(7)Å b=36.592(3)Å c=5.4266(2)Å
α=95.006(4)° β=101.463(3)° γ=84.613(6)°
Β~2~-3 LaOLa
C45H84O6
Acta Crystallographica Section B (2008) 64, 6 771-779
a=5.44890(6)Å b=104.424(3)Å c=8.14280(14)Å
α=90.0° β=88.5014(11)° γ=90.0°
Β-3 LaOLa
C45H84O6
Acta Crystallographica Section B (2008) 64, 6 771-779
a=5.49980(9)Å b=7.73590(4)Å c=56.101(2)Å
α=81.4578(12)° β=89.685(2)° γ=90.2130(6)°
Hydrated sodium cytidine-5'-monophosphate
2Na1,C9H4N3O8P2,6.5H6O
Acta Crystallographica Section E (2001) 57, 11 m514-m516
a=14.042(2)Å b=8.924(2)Å c=16.091(3)Å
α=90.00° β=94.410(2)° γ=90.00°
5,5-Dimethyl-2-[6-methyl-2-(methylsulfanyl)pyrimidin-4-yloxy]- 1,3,2-dioxaphosphorinane-2-thione
C11H17N2O3PS2
Acta Crystallographica Section C (2002) 58, 5 o280-o281
a=9.900(2)Å b=9.330(2)Å c=17.010(3)Å
α=90° β=90.23(2)° γ=90°